Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Vantictumab (OMP-18R5), a fully human IgG2 monoclonal antibody, antagonizes Wnt pathway signaling through binding to FZD1/2/5/7/8 receptors. It is currently under investigation for the treatment of various cancers, including metastatic HER2-negative breast cancer and metastatic pancreatic adenocarcinoma [1] [2].
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | Inquiry | Inquiry | |
5 mg | Inquiry | Inquiry |
Description | Vantictumab (OMP-18R5), a fully human IgG2 monoclonal antibody, antagonizes Wnt pathway signaling through binding to FZD1/2/5/7/8 receptors. It is currently under investigation for the treatment of various cancers, including metastatic HER2-negative breast cancer and metastatic pancreatic adenocarcinoma [1] [2]. |
Synonyms | OMP-18R5 |
Molecular Weight | N/A |
CAS No. | 1345009-45-1 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Vantictumab 1345009-45-1 OMP-18R5 inhibitor inhibit